

## Asparaginase Hypersensitivity and Silent Inactivation in Pediatric and AYA Patients with ALL

### References

1. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. *J Exp Med*. 1953;98:565-582.
2. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. *J Exp Med*. 1963;118:121-148.
3. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. *Blood*. 2000;96:1709-1715.
4. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. *Blood*. 2001;97:1211-1218.
5. Sigma-Tau Pharmaceuticals, Inc. Oncaspar® (pegaspargase) [package insert].
6. Servier Pharmaceuticals. Asparlas™ (calaspargase pegol-mknl) [package insert].
7. Jazz Pharmaceuticals, Inc. Asparaginase *Erwinia chrysanthemi* (recombinant) [package insert].
8. Van der Sluis IM, Vrooman M, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. *Hematologica*. 2016;101(3):279-285.
9. US Dept. of Health and Human Services. NIH. NCI. CTCAE. V 5.0. 2017. [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/CTCAE\\_v5\\_Quick\\_Reference\\_8.5x11.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf). Accessed January 19, 2022.
10. Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. *Leuk Lymphoma*. 2017;58(3):540-551.
11. Swanson HD, Panetta JC, Barker PJ, et al. Predicting success of desensitization after pegaspargase allergy. *Blood*. 2020;135(1):71-75.
12. Bleyer A, et al. Clinical application of asparaginase activity levels following treatment with pegaspargase. *Pediat Blood Cancer*. 2015;62:1102-1105.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Jazz Pharmaceuticals and Servier Pharmaceuticals, LLC.